PHARVARIS NV

Insider sale by Pharvaris CEO Modig Berndt adds 2,292 shares at €34.97, a planned move in a high‑valuation window that keeps investor confidence steady while funding future trials.

Insight on Pharvaris NV insider sales: Schikan’s 10(b)(5) trades may signal short‑term profit‑taking while fundamentals remain bullish for long‑term investors.

Insider sales at Pharvaris: CEO Modig Berndt’s routine 2,191‑share June sale reflects rule‑based liquidity, not a strategic shift, but a rising trend may hint at take‑profit sentiment.

Pharvaris insider sales reveal routine portfolio moves, not loss of faith, yet investors should watch clinical milestones and price volatility.

Insider moves reveal Pharvaris NV’s strategic shift, with key buys at €8.05 and sales at €29.32—an insider‑confidence signal for investors.

Pharvaris NV insider selling rises—CEO Modig Berndt sells thousands of shares at $29.22, sparking short‑term volatility amid a strong 101% annual gain and promising oral B2 antagonist pipeline. Invest with insight.

Pharvaris NV insiders trade a mixed‑bag deal on May 15, 2026—Glassman buys at $22.31 and sells at $29.82‑$29.83, signaling bullish confidence amid rising stock.

Pharvaris insider sale: CMO Lu Peng’s routine liquidity move shows long‑term confidence amid a 120% rally and Phase‑3 data anticipation.

Pharvaris insider sales show routine 10b5‑1 divestitures, no sharp price impact—focus remains on strong quarterly results and future clinical milestones.

Pharvaris insider trades reveal executives buying at €2.59 and selling around €30, showing confidence in the company’s rare‑disease pipeline and future milestones.